Maria P Brizzi

Summary

Country: Italy

Publications

  1. ncbi The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
    Stephen B Fox
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Breast Cancer Res 13:R16. 2011
  2. ncbi Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network
    Maria P Brizzi
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera San Luigi, Regione Gonzole, 10, 10043 Orbassano TO, Italy
    BMC Cancer 9:388. 2009

Collaborators

  • Luigi Dogliotti
  • Alfredo Berruti
  • Stephen B Fox
  • Alessandra Bersiga
  • Leticia Campo
  • Giovanni Allevi
  • Daniele Generali
  • Sergio Aguggini
  • Adrian L Harris
  • Teresa Mele
  • Alberto Bottini
  • Manuela Milani
  • Simone Bonardi

Detail Information

Publications2

  1. ncbi The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
    Stephen B Fox
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Breast Cancer Res 13:R16. 2011
    ....
  2. ncbi Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network
    Maria P Brizzi
    Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Azienda Ospedaliera San Luigi, Regione Gonzole, 10, 10043 Orbassano TO, Italy
    BMC Cancer 9:388. 2009
    ..A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma...